A unique commercially viable recombinant manufacturing platform for human fibrinogen (rhFib) & thrombin (rhThr

€4.5M EUR

Funder	European Commission
Recipient Organization	Fibriant Bv
Country	Netherlands
Start Date	Apr 01, 2022
End Date	Dec 31, 2023
Duration	639 days
Number of Grantees	1
Roles	Coordinator
Data Source	European Commission
Grant ID	`190183175`

Grant Description

We have developed the RECOFIB platform, a market first recombinant production platform for human fibrinogen (rhFib) & thrombin (rhThr).

Using Chinese Hamster Ovary Cells (CHO) expression technology & patented upstream purification processes, we are the first producer of fully intact & functional recombinant fibrinogen and active thrombin at commercially acceptable cost ending reliance on blood plasma.

Our RECOFIB platform can produce individual fibrinogen variants whose specific functional properties can now be fully harnessed-a breakthrough discovery.

From these individual variants, we can develop customized products for [1] bioactive topical hemostats to stop excessive bleeding during surgery; [2] medical implant coating reducing antibiotic resistance of MRSA bacterial biofilms and [3] supply of rhFib variants & rhThr as OEM products.

Additional benefits of our rhFib variants compared to plasma fibrinogen include more stability, 10100X higher purity, and improved safety profile.